Products - Metabolic conditions | Topic | NICE

Showing 8 products

Date | Title

Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 December 2025
Pegzilarginase for treating arginase-1 deficiency [ID4029]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
20 February 2026
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 March 2026
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Efzimfotase alfa for treating hypophosphatasia in people 12 years and over [ID6633]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC